Expert Systems, a leading provider in drug discovery acceleration, has recently announced a Series A funding round and the launch of Mondego Bio, an innovative company focused on immuno-oncology. Mondego Bio is headquartered in Biocant Park, located in Cantanhede, Portugal, a hub that fosters biotechnology research and development. This new venture is backed by notable investment firms, including Biovance Capital, Torrey Pines Investment, and OrbiMed, all of which are recognized for their strategic investments in the life sciences.
The primary goal of Mondego Bio is to develop a diverse portfolio of first- and best-in-class PTPN2 inhibitors, which have the potential to revolutionize cancer immunotherapy. These inhibitors are specifically designed to address one of the most pressing challenges in oncology: overcoming immune resistance in solid tumors. By employing proprietary technology and expertise, Mondego Bio’s PTPN2 inhibitors are engineered to possess oral bioavailability, high selectivity, and favorable safety and tolerability profiles. These characteristics position them as promising candidates for integration into advanced combination immuno-oncology regimens.
The science behind Mondego Bio’s drug candidates leverages Expert Systems’ cutting-edge artificial intelligence (AI) and machine learning (ML)-driven molecular design and predictive pharmacology platform. This advanced technology not only enhances the design of the inhibitors but also accelerates the timeline from initial concept to clinical readiness, allowing for a faster transition into human trials.
As Mondego Bio prepares to advance its pipeline into first-in-human studies, Expert Systems will continue to provide essential strategic, scientific, and technological support. This ongoing collaboration highlights Expert Systems’ distinctive ability to develop and scale high-value biotech ventures, thereby effectively mitigating the risks associated with early-stage innovation for investors and partners. By leveraging synergies between their platforms and expertise, both companies aim to make a significant impact in the field of cancer treatment and enhance patient outcomes.
KEY QUOTES:
“Solid tumors remain one of the greatest unmet needs in medicine. By integrating predictive ADMET and PK/PD modeling with in-silico and in vitro new-approach methodologies (NAMs), we gave Mondego Bio a decisive edge — identifying high-potential PTPN2 inhibitors and accelerating their journey into development.”
Dr. Tudor Oprea, CEO of Expert Systems
